Company intelligence / Profile preview

Ab Frontier

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~50
Development stage: Other

Overview

AbFrontier is a South Korean biotechnology company specializing in the development and manufacture of high-quality antibodies and proteins. The company is particularly recognized for its extensive portfolio of antibodies targeting Reactive Oxygen Species (ROS) and its proprietary "Long-tail" antibody technology. Beyond its product catalog, AbFrontier provides comprehensive contract research services, including custom antibody production and assay development. Their products support global research in oncology, metabolic diseases, and neurodegeneration.

Therapeutic areas: OncologyNeurologyMetabolic Disorders
Modalities: Monoclonal antibodyPolyclonal antibodyRecombinant protein
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Ab Frontier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ab Frontier.

Explore the full profile